Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Switch Success: Paxil CR Has 31% Of New Scripts; Augmentin ES, 49%

Executive Summary

GlaxoSmithKline has converted 31% of Paxil new prescriptions to the controlled-release version

You may also be interested in...



GSK Wellbutrin XL Approval Pressures Generics to Launch SR Formulation

The approval of GlaxoSmithKline's Wellbutrin XL puts pressure on generic firms to launch their sustained-release versions of the antidepressant

GSK Wellbutrin XL Approval Pressures Generics to Launch SR Formulation

The approval of GlaxoSmithKline's Wellbutrin XL puts pressure on generic firms to launch their sustained-release versions of the antidepressant

GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals

GlaxoSmithKline's delisting of three Paxil patents will clear the way for approval of generic versions of the antidepressant, and set up a potential dispute over how 180-day exclusivity will be awarded

Related Content

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel